A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes

NCT01976858 · Completed

Last updated 2026-05-28

This clinical trial tested an 8-week treatment with polyethylene glycol loxenatide in people with type 2 diabetes to measure its levels in the blood.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 50 people

Who can join Ages 20–65 · all sexes

Timeline Started 2011-06 · est. completion 2011-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT01976858 ↗

Description as written by the study sponsor.

Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG). This study aims to evaluate the PK, PD and safety by 8-week continuous treatment of PEX168.

Treatments tested

PEX168 also known as Polyethylene Glycol Loxenatide Drug

A injection administered subcutaneously

Main thing measured	To determine serum concentrations of PEX168
Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01976858 ↗